References:
1. Townsend L and Martin-Loeches I. Diagnostics. 2022;12(11):2712.
2. Taccone FS et al. Crit Care. 2015;19(1):7.
3. Verweij PE et al. Intensive Care Med. 2020;46(8):1524–1535.
4. Crum-Cianflone NF. Open Forum Infect Dis. 2016;3:ofw171.
5. Bongomin F et al. J Fungi (Basel). 2017;3(4):57.
6. Kosmidis C and Denning DW. Thorax. 2015;70(3):270–277..
7. AmBisome® Summary of Product Characteristics (UK). Available at:
https://www.medicines.org.uk/emc/product/1022/smpc#gref.
[Last accessed: March 2023].
8. Lass-Flörl C et al. Antimicrob Agents Chemother. 2008;52(10):3637–3641.
9. Chandrasekar P. J Antimicrob Chemother. 2011;66(3):457–465.
10. Meletiadis J et al. J Antimicrob Agents Chemother. 2007;51(9):3329–3337.
11. Cornely OA et al. Clin Infect Dis. 2007;44(10):1289–1297.
12. Cornely OA et al. Mycoses. 2011;54(5):e449–e455.
13. Falci DR. Infect Dis Ther. 2017;6(2):213–223.
14. Bassetti M et al. Crit Care. 2014;18(8):458.
15. Manavathu EK et al. Antimicrobial Agents And Chemotherapy.
1998;42(11):3018–3021.
16. Van de Veerdonk FL, et al. Am J Respir Crit Care Med.
2020;202(5):646–648.
17. Gao Y, et al. Adv Respir Med. 2019;87(6):231–243.
18. Jenks JD, et al. J Fungi (Basel). 2018;4(3):98.
19. Tashiro M et al. J Infect Chemother. 2021;27(10):1471–1476.
20. Nivoix Y et al. Clin Infect Dis. 2008;47(9):1176–1184.
21. Martin-Loeches I et al. Intensive Care Med. 2019;45(6):789–805.
References:
1. Townsend L and Martin-Loeches I. Diagnostics. 2022;12(11):2712.
14. Bassetti M et al. Crit Care. 2014;18(8):458.
15. Manavathu EK et al. Antimicrobial Agents And Chemotherapy. 1998;42(11):3018–3021.
16. Van de Veerdonk FL, et al. Am J Respir Crit Care Med. 2020;202(5):646–648.
17. Gao Y, et al. Adv Respir Med. 2019;87(6):231–243.
18. Jenks JD, et al. J Fungi (Basel). 2018;4(3):98.
19. Tashiro M et al. J Infect Chemother. 2021;27(10):1471–1476.
20. Nivoix Y et al. Clin Infect Dis. 2008;47(9):1176–1184.
21. Martin-Loeches I et al. Intensive Care Med. 2019;45(6):789–805.
2. Taccone FS et al. Crit Care. 2015;19(1):7.
3. Verweij PE et al. Intensive Care Med. 2020;46(8):1524–1535.
4. Crum-Cianflone NF. Open Forum Infect Dis. 2016;3:ofw171.
5. Bongomin F et al. J Fungi (Basel). 2017;3(4):57.
6. Kosmidis C and Denning DW. Thorax. 2015;70(3):270–277..
7. AmBisome® Summary of Product Characteristics (UK). Available at:
https://www.medicines.org.uk/emc/product/1022/smpc#gref.
[Last accessed: March 2023].
8. Lass-Flörl C et al. Antimicrob Agents Chemother. 2008;52(10):3637–3641.
9. Chandrasekar P. J Antimicrob Chemother. 2011;66(3):457–465.
10. Meletiadis J et al. J Antimicrob Agents Chemother. 2007;51(9):3329–3337.
11. Cornely OA et al. Clin Infect Dis. 2007;44(10):1289–1297.
12. Cornely OA et al. Mycoses. 2011;54(5):e449–e455.
13. Falci DR. Infect Dis Ther. 2017;6(2):213–223.
This educational tool is developed and fully funded by Gilead Sciences, and it is intended for healthcare
professionals only. It contains information about Gilead products, educational materials on therapy areas,
and professional resources.
Prescribing information for Liposomal Amphotericin B